Cancer clinical trials in the region Auvergne-Rhône-Alpes
495 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Sarcoma and GIST
#NCT02275286
#2024-518199-30-00
Cohorte C
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required previous treatments at localized stage
Systemic Treatment-Naive
Required soft tissue sarcoma locations
Retroperitoneum
Excluded previous treatments at localized stage
Surgery
Chemotherapy
Radiotherapy
2 recruiting sites
Grupo Espanol de Investigacion en Sarcomas
Phase 1 / Phase 2
Sarcoma and GIST
#NCT06797999
#2024-516900-41-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Adcendo ApS
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
[Horizen-1 Étude de phase 1/2 de l'Enzomenib (DSP-5336) chez les patients atteints de leucémie aiguë
Phase 1, Bras L, M et N
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
#2022-502741-10-00
Phase 2, Bras G, H et K
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
MLL fusions
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
Phase 2, bras J
Required genetic anomalies
MLL fusions
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Acute leukemia
#NCT04988555
#2022-502741-10-00
Phase 2 - Bras I
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2
Lung cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT06923761
#2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Esophagus
Invasive bladder cancer
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma
Squamous cell carcinoma
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics
Phase 1 / Phase 2
Lung cancer
#NCT06128551
Phase 1b expansion de dose et phase 2 cohortes CBNPC non naïf d'inhibiteurs de KRAS G12C
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2
Colon cancer
Rectal cancer
#NCT06934538
#2024-512011-45-00
Phase 1 et Phase 2A Bras 2A-1
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other KRAS
KRAS G12C
KRAS non G12C
MSS/pMMR
KRAS G12D
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
5 recruiting sites
Brenus Pharma
Phase 1 / Phase 2
Lung cancer
#NCT06162221
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other KRAS
HRAS
KRAS G12C
KRAS non G12C
KRAS G12D
NRAS
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Revolution Medicines, Inc.